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Background: Local epidemiological data are always helpful when choosing the best antibiotic
regimen, but it is more complex than it seems as it may require the analysis of multiple com-
binations. The aim of this study was to demonstrate a simpliﬁed mathematical calculation
to  determine the most appropriate antibiotic combination in a scenario where monotherapy
is  doomed to failure.
Methods: The susceptibility pattern of 11 antibiotics from 216 positive blood cultures from
January 2012 to January 2013 was analyzed based on local policy. The length of hospitaliza-
tion  before bacteremia and the unit (ward or intensive care unit) were the analyzed variables.
Bacteremia was classiﬁed as early, intermediate or late. The antibiotics were combined
according to the combination model presented herein.
Results: A total of 55 possible mathematical associations were found combining 2 by 2,
165  associations with 3 by 3 and 330 combinations with 4 by 4. In the intensive care unit,
monotherapy never reached 80% of susceptibility. In the ward, only carbapenems covered
more  than 90% of early bacteremia. Only three drugs combined reached a susceptibility rate
higher  than 90% anywhere in the hospital. Several regimens using four drugs combinedreached 100% of susceptibility.
Conclusions: Association of three drugs is necessary for adequate coverage of empirical treat-
n bo
sufﬁcient to overcome this problem. In different hospitals, thement  of bacteremia i
Introduction
Antibiotic therapy is essential for the proper treatment of
infections.1 For community-acquired infections, protocols or
consensus guidelines are extremely useful, since the suscep-
tibility proﬁle of bacteria may be quite similar in many  areas
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of the world. Even when there are differences in antimicrobial
susceptibility, administration of a large-spectrum antibiotic is, Hospital Universitário Evangélico de Curitiba, Alameda Augusto
ritiba, Brazil.
data collection and manuscript writing.
ideal choice of antibiotics is hampered by extensive variability
of bacteria and susceptibility proﬁles. Thus, the establishment
of a consensus by the medical societies, even for regional
eserved.
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(31.5%), followed by Klebsiella spp. (13.4%). The species distri-
bution is detailed in Table 1. Early bacteremia (44.0%) was more
frequent than late (34.7%) and intermediate (21.3%) (p < 0.05).
Table 1 – Bacterium species of 216 bacteremia in a
hospital during January 2012 to January 2013.
Bacteria n %
Staphylococcus aureus MSSA 46 21.5
Klebsiella spp. 29 13.4
Acinetobacter baumannii 24 11.0
Staphylococcus aureus MRSA 22 10.0
Streptococcus spp. 22 10.2
Enterobacter spp. 16 7.4
Escherichia coli 16 7.4
Serratia spp. 14 6.5
Pseudomonas aeruginosa 11 5.1
Enterococcus spp. 7 3.2
Citrobacter spp. 3 1.4
Proteus spp. 3  1.4
Haemophilus spp. 1 0.5b r a z j i n f e c t d i s .
ntities, is rather challenging. Therefore, each hospital must
ssess its microbiological proﬁle and propose treatment rec-
mmendations and protocols based on local data.
The knowledge of the local susceptibility proﬁle can be
sed for choosing monotherapy. However, selecting the best
ntibiotic combination is far more  complex since it involves
ynamic calculations of the combination. Additionally, three
o four drugs may be required to achieve an adequate coverage
n high resistance scenarios, and this will generate hundreds
f possible combinations.
The aim of this study was to demonstrate a simpliﬁed
athematical calculation to determine the most appropriate
ntibiotic association, considering dynamic but easily acces-
ible epidemiological variables.
aterials  and  methods
 cross-sectional study was carried out at the Hospital
niversitário Evangélico de Curitiba, a 660-bed tertiary-care
niversity hospital in Curitiba, Brazil. This hospital is refer-
nce for renal transplantion, trauma and burn. All patients
ged ≥18 years with a positive blood culture collected from
anuary 2012 to January 2013 were included in the study. Only
he ﬁrst episode per patient was analyzed. Blood cultures
ielding coagulase-negative Staphylococcus were considered
ontaminated and thus excluded. Data were collected from
ospital computer system databases.
Blood cultures were collected according to the standard
rotocol used in the hospital and were processed using
he BACT/Alert® (BioMerieux, Durham, USA). Bacteria were
dentiﬁed by Vitek 2 (Biomérieux, Marcy-L’Étoile, France). Sus-
eptibility testing was performed using the disk diffusion
ethod according to the CLSI guidelines.2 Molecular conﬁr-
ation of extended and pan-resistant strains was routinely
one.
The susceptibility pattern of 11 antibiotics was ana-
yzed. The choice was based on local policy: aminoglycosides
amikacin and gentamycin), semi-synthetic penicillin with
eta-lactamases inhibitor (ampicillin/sulbactam), third and
ourth generation of cephalosporins (ceftriaxone, ceftazidime
nd cefepime), ﬂuoroquinolones (ciproﬂoxacin and levo-
oxacin), ureidopenicillin with beta-lactamase inhibitor
piperacillin/tazobactam), glycopeptides (vancomycin and
eicoplanin), polymyxin, carbapenems (meropenem and
mipenem) and tetracyclines (tigecycline). For statistical anal-
sis, aminoglycosides and carbapenems were considered to be
esistant if any of the tested antibiotics in the same class was
dentiﬁed as resistant (e.g. if amikacin was susceptible and
entamycin resistant, the aminoglycoside group was consid-
red resistant). Ceftazidime and ceftriaxone were evaluated
eparately. Tigecycline was included in the analysis once the
ncidence of KPC-producing Klebsiella pneumoniae was high in
his hospital.3
The length of hospitalization before bacteremia and the
nit (ward or intensive care unit – ICU) were the variables
nalyzed. Bacteremia was classiﬁed as early (<6 days), inter-
ediate (6–14 days) and late (>14 days). This classiﬁcation was
reated just for clinical purposes in the hospital.4;1 8(4):360–363 361
For assessing combinations, the antibiotics were combined
2 by 2, 3 by 3, and 4 by 4 according to the following combination
formula:(
s
n
)
= n!
s!(n − s)!
where “n” is the number of antibiotics and “s” the number of
combined antibiotics.
A large table was assembled to evaluate the percentage
of antibiotic susceptibility for each bacterium to each group
of antibiotic and for each combination of antibiotics (2 by
2, 3 by 3, and 4 by 4) (supplement table, http://infectopedia.
com/dados-estatisticos/category/6-dados-estatisticos). When
combinations were analyzed, the bacteria were considered
susceptible for that combination if at least one antibiotic was
active. The percentages in the table are the susceptibility rates
against all bacteria during the period (100% for total suscepti-
bility and 0% for no susceptibility).
Statistical  analysis
Continuous data are expressed as mean ± standard deviation
(SD) or median with ranges. Frequencies are expressed as per-
centages. Dichotomous variables were compared using 2 test
and Mann–Whitney test was used for continuous variables.
Signiﬁcance level was set at 0.05.
All data were recorded using the software Excel (Microsoft,
New York, USA) and the statistical analysis was performed
using the software SPSS 16 (SPSS, Chicago, USA). GraphPad
Prism 5.0 (GraphPad, La Jolla, USA) was used for graphics.
Results
A total of 216 bacteremias were evaluated. Staphylococcus
aureus was the most common bacteria found in the studyProvidencia spp. 1 0.5
Stenotrophomonas maltophila 1 0.5
Total 216 100.0
362  b r a z j i n f e c t d i s . 2 0 1 4;1  8(4):360–363
Table 2 – Susceptibility pattern of each antibiotic for bacteria recovered from 216 bacteremia classiﬁed as early (< 5 days),
intermediate (5 – 14 days) and late (>14 days). The bacteremia cases were categorized as from the intensive care unit or
from the clinical ward.
Antibiotic Ward (n = 146) Intensive care unit (n = 70)
Early (%) Intermediate (%) Late (%) Early (%) Intermediate (%) Late (%)
Aminoglycoside 26.3 33.3 27.9 21.10 26.30 34.40
Ampicillin–sulbactam 75.0 28.6 34.8 47.40 31.60 50.00
Cefepime 84.2 44.4 39.6 52.60 47.40 50.00
Ceftazidime 22.4 0.0 13.9 10.50 15.80 15.60
Ceftriaxone 75.0 14.8 23.5 36.80 36.80 31.30
Fluoroquinolone 81.6 48.5 39.5 63.20 47.40 50.00
Carbapenem 92.1 59.2 48.8 68.40 47.40 71.90
Piperacillin–tazobactam 80.3 37.0 41.8 63.20 36.80 56.30
Polymyxin 26.3 37.0 
Glycopeptide 67.1 44.4 
Tigecycline 84.2 88.9 
Bacteremia was more  frequent in the ward (67.6%) than in the
intensive care unit (32.4%) (p < 0.05).
Using the combination formula, 55 associations were found
combining 2 by 2, 165 associations with 3 by 3, and 330 combi-
nations with 4 by 4. A total of 561 options for treatment were
available.
The susceptibility to antimicrobials with respect to the
unit of admission and length of hospitalization is detailed in
Table 2. In the ICU, no antibiotic reached 80% of susceptibil-
ity, with the exception of tigecycline (87%). This drug is not
indicated for severely ill patients, and we  excluded it from the
analysis. Based on these data, one antibiotic is not enough as
empirical treatment for bacteremia in the ICU setting. In the
ward, early bacteremia showed better susceptibility pattern,
with four antibiotics (cefepime, piperacillin/tazobactam, ﬂuo-
roquinolone, and tigecycline) having more  than 80–90%, and
one (carbapenems) having 92% coverage. However, suscepti-
bility rate was lower than 60% for all antibiotics (excluding
tigecycline) in case of intermediate and late bacteremia.
Detailed rates of susceptibility for combined therapy are
available as supplement material or at the site INFECTOPE-
DIA (http://infectopedia.com/dados-estatisticos/category/6-
dados-estatisticos). In the table there are redundant antibi-
otic combinations such as cefepime with ceftriaxone. These
combinations were included in the table just for statistical
analysis, but must not be considered as clinical options for
therapy.
In the ward, monotherapy for intermediate and late
bacteremia had low coverage (up to 59% and up to 56%,
respectively). Combination of two antibiotics reached a maxi-
mum of 85% susceptibility with carbapenem plus glycopeptide
for intermediate bacteremia, and 83% for late bacteremia
with carbapenem plus polymyxin. Only three drugs combined
reached a coverage higher than 90%, using polymyxin plus
glycopeptide associated with one of three options (cefepime,
ﬂuorquinolone or aminoglycoside).
For intermediate bacteremia in the ICU, two combined
antibiotics reached a susceptibility rate of 89% for glycopep-
tide plus polymyxin, 89% for carbapenem plus polymyxin, and
95% for polymyxin plus ﬂuoroquinolone. Tigecycline was not
included in this analysis as it was not indicated for use in bac-
teremic patients. For late bacteremia, the same regimen using
carbapenem plus polymyxin reached 91%, which increased55.8 42.10 57.90 37.50
25.5 42.10 31.60 28.10
81.4 84.20 78.90 93.80
to 97% by adding a glycopeptide. Several regimens using four
drugs combined reached 100% susceptibility.
Discussion
There are several publications showing the importance of an
adequate antibiotic for the treatment of severe infections.4–7
Inadequate antibiotic therapy can increase mortality to a vary-
ing extent according to the population studied, severity of
infection, clinical underlying conditions, and other epidemio-
logical variables.8 However, other studies have not conﬁrmed
these ﬁndings, mainly in case of bacteremia in the ICU setting
with comorbidities and advanced age.3,9,10
However, none of these studies deﬁned the ideal rate of
antibiotic coverage, regardless of the patient’s clinical condi-
tions. The question is: what should be the acceptable margin of
error in the prescription of antibiotics for bacteremic patients?
The ideal is 100% adequacy, but this ﬁgure can only be reached
with at least three drugs, a suggestion not found in guidelines,
including the IDSA guidelines for developing an institutional
program to enhance antimicrobial stewardship.11
One could extensively discuss this issue. Several factors
inﬂuence the decision of the physician when prescribing the
antibiotic therapy, such as disease severity, patient age, comor-
bidities, organ dysfunction, previous colonization/infection,
and probable site of infection. In some cases, it might be pos-
sible to delay the choice of antibiotics until the ﬁnal result
of cultures. However, in patients with severe sepsis, the deci-
sion must be taken in the ﬁrst hours.12 Laboratory tests to
identify bacteria and their susceptibility pattern to antibiotics
in this window of time are not a reality yet.13 Nonetheless,
when properly collected, culture results will allow the clinician
to de-escalate all drugs to a broad spectrum speciﬁc therapy.
De-escalation may be performed as soon as the result of Gram-
positive blood culture is obtained, and it may be performed
again after ﬁnal identiﬁcation.
Other questions about antibiotic prescription are: to deter-
mine if the patient is really infected; to consider candidemia
or other fungi; how to de-escalation when blood cultures are
negative; additional epidemiological variables may improve
empirical decisions.
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This simulation must be validated considering the follow-
ng facts: (1) most cases of “fever” and laboratory alterations
mainly leukocytosis with immature cells) are not infection;
2) the infection is not severe, and we  can wait for culture
esults; (3) the need for and effectiveness of antibiotic ther-
py in terminal patients; (4) side effects of extremely toxic
ssociations (e.g. vancomycin, polymyxin, aminoglycoside);
nd (5) resistance induction and microbiote modiﬁcation with
urther superinfection or Clostridium difﬁcile colitis. Although
ombined therapy may be used for a short period, con-
tant vigilance and follow up by an infectious diseases
pecialist is mandatory. Falagas et al. published an inter-
sting article where they suppose that 50% of fever is not
nfection.14
The current results are the epidemiological panorama of a
niversity hospital in a developing country, which cannot be
pplied to other health services and hospitals. The combina-
ion of three or four drugs can be used as a policy of antibiotic
estriction. Carbapenems may be avoided with a regimen of
iproﬂoxacin + piperacillin/tazobactam. This can be an option
n hospitals that practice antibiotic cycling.
Some bias probably may have occurred in this study, once
atients with bacteremia in the ward had been previously
dmitted at the ICU, falsely increasing the rate of resistant
n the ward.
The current study does not have the intention to con-
ince clinicians to use bizarre and threatening antibiotic
ombinations, but rather to consider revision of current local
uidelines and consider the mathematical formula of combi-
ation to construct an ideal regimen in that context. The same
pproach can be used for other infections, including urinary
ract and respiratory infections, although one should consider
ultures obtained from these sites. After this study, our hospi-
al changed the antibiotic protocol for treating bacteremia, and
ther studies will be conducted in different sites. An internal
alidation must be performed followed by an external vali-
ation, if possible.
Antibiotic regimens with two, three or even four antibiotics
eem so remote from what is currently considered to be good
ntibiotic prescribing practice that it may be difﬁcult to be
pplied in clinical practice.
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